Rubicon Research (RUBICON) Stock Overview
Operates as a specialty pharmaceutical company in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RUBICON Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Rubicon Research Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,439.60 |
| 52 Week High | ₹1,527.00 |
| 52 Week Low | ₹570.75 |
| Beta | 0 |
| 1 Month Change | 10.12% |
| 3 Month Change | 60.15% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 129.16% |
Recent News & Updates
We Think That There Are Issues Underlying Rubicon Research's (NSE:RUBICON) Earnings
Rubicon Research Limited's ( NSE:RUBICON ) stock was strong after they recently reported robust earnings. However, we...Rubicon Research Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Rubicon Research Limited ( NSE:RUBICON ) just released its full-year report and things are looking bullish. The company...Recent updates
Shareholder Returns
| RUBICON | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.6% | -0.8% | -0.2% |
| 1Y | n/a | 10.5% | -0.5% |
Return vs Industry: Insufficient data to determine how RUBICON performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RUBICON performed against the Indian Market.
Price Volatility
| RUBICON volatility | |
|---|---|
| RUBICON Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: RUBICON's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: RUBICON's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Parag Sancheti | www.rubicon.co.in |
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant.
Rubicon Research Limited Fundamentals Summary
| RUBICON fundamental statistics | |
|---|---|
| Market cap | ₹237.17b |
| Earnings (TTM) | ₹2.47b |
| Revenue (TTM) | ₹17.54b |
Is RUBICON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RUBICON income statement (TTM) | |
|---|---|
| Revenue | ₹17.54b |
| Cost of Revenue | ₹5.56b |
| Gross Profit | ₹11.98b |
| Other Expenses | ₹9.51b |
| Earnings | ₹2.47b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.98 |
| Gross Margin | 68.30% |
| Net Profit Margin | 14.07% |
| Debt/Equity Ratio | 20.1% |
How did RUBICON perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/18 19:47 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rubicon Research Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anshuman Gupta | Investec Bank plc (UK) |
| null null | Motilal Oswal Securities Ltd. |
| Tushar Manudhane | Motilal Oswal Securities Ltd. |